Biovail, Canada’s largest publicly owned pharmaceutical company, is to take over US-based Valeant Pharmaceuticals International in a transformational deal, valued at approximately US$3.3 B, that will see it strengthen its presence in North America and expand into emerging international markets and a second therapy area.